Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Franco Fortunato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6711-5828; OpenAlex author ID A5074997877. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 3 papers

Papers 12

  1. Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41388-026-04026-x↗
  2. Tumor Location and Preoperative Biliary Stenting Shape Gut Microbiome Diversity in Pancreatic Cancer. First author DOI 10.3390/cancers18162617↗
  3. Preoperative biliary stenting is associated with functional dysbiosis and impaired bile acid metabolism in pancreatic cancer - Impact of preoperative biliary s… Co-author DOI 10.64898/2026.05.19.719953↗
  4. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  5. Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.28527↗
  6. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6↗
  7. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.matbio.2022.11.002↗
  8. Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.27399↗
  9. Sulforaphane enhances irradiation effects in terms of perturbed cell cycle progression and increased DNA damage in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0180940↗
  10. Phytotherapeutics Oridonin and Ponicidin show Additive Effects Combined with Irradiation in Pancreatic Cancer in Vitro. Co-author DOI 10.1515/raon-2017-0048↗
  11. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3171↗
  12. Autophagy and cell death signaling following dietary sulforaphane act independently of each other and require oxidative stress in pancreatic cancer. Co-author DOI 10.3892/ijo.2011.1025↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christoph W. Michalski · 4 shared papers, 2024–2026 · strength 0.83
  2. Thomas P. Hank · 3 shared papers, 2026 · strength 0.69
  3. Max Heckler · 3 shared papers, 2026 · strength 0.69
  4. Martin Loos · 3 shared papers, 2024–2026 · strength 0.60
  5. Thilo Hackert · 5 shared papers, 2015–2024 · strength 0.59
  6. Ingrid Herr · 4 shared papers, 2015–2026 · strength 0.58
  7. Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.47
  8. Marionna Cathomas · 2 shared papers, 2026 · strength 0.47
  9. Jonathan M. Harnoss · 2 shared papers, 2026 · strength 0.47
  10. Rogier Aäron Gaiser · 2 shared papers, 2026 · strength 0.47
  11. Bo Kong · 2 shared papers, 2026 · strength 0.47
  12. Peer Bork B · 2 shared papers, 2026 · strength 0.47
  13. Oliver Strobel · 4 shared papers, 2015–2024 · strength 0.45
  14. John P. Neoptolemos · 3 shared papers, 2019–2024 · strength 0.36
  15. Li Liu · 3 shared papers, 2015–2024 · strength 0.36
  16. Peter J. Bailey · 2 shared papers, 2023–2024 · strength 0.27
  17. Shigenori Ei · 2 shared papers, 2023–2024 · strength 0.27
  18. Jingyu An · 2 shared papers, 2023–2024 · strength 0.27
  19. Christoph Springfeld · 2 shared papers, 2023–2024 · strength 0.27
  20. Xu Zhou · 2 shared papers, 2023–2024 · strength 0.27
  21. Nathalie Bauer · 2 shared papers, 2015–2024 · strength 0.23
  22. Nathalia A. Giese · 2 shared papers, 2015–2024 · strength 0.23
  23. Alexandr V. Bazhin · 2 shared papers, 2015–2024 · strength 0.23
  24. Eduard Ryschich · 2 shared papers, 2015–2024 · strength 0.23
  25. Pei Fan · 2 shared papers, 2015–2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.